Literature DB >> 11226385

Inhibition by ginkgolides and bilobalide of the production of nitric oxide in macrophages (THP-1) but not in endothelial cells (HUVEC).

F Cheung1, Y L Siow, K O.   

Abstract

Nitric oxide (NO) is a principal mediator in many physiological and pathological processes. NO produced by constitutive nitric oxide synthase in endothelial cells (eNOS) acts as a vasodilator, whereas excess NO production due to elevated expression of inducible nitric oxide synthase (iNOS) may produce cytotoxic effects to cells in the vascular wall. We demonstrated in our previous work that the extract of Ginkgo biloba leaves (EGb) inhibits iNOS-mediated NO production. The objective of the present study was to investigate the effects of several active EGb components on iNOS-mediated NO production in macrophages derived from a human monocytic cell line (THP-1), as well as on eNOS-mediated NO production in human umbilical vein endothelial cells (HUVEC). Ginkgolide A, ginkgolide B, or bilobalide (0.25 to 1.0 microg/mL) caused a 30-65% reduction in the levels of NO metabolites released by THP-1 macrophages after 4 hr of incubation, with a corresponding decrease in iNOS activity. Western immunoblotting analysis coupled with a nuclease protection assay and reverse transcription-polymerase chain reaction revealed a concomitant reduction in the levels of iNOS protein mass and mRNA in ginkgolide A-, ginkgolide B-, or bilobalide-treated macrophages. On the other hand, these compounds did not affect eNOS-mediated NO production or the expression of eNOS protein and mRNA in HUVEC. Taken together, these results suggest that ginkgolide A, ginkgolide B, and bilobalide may contribute to the selective inhibitory effect of EGb on iNOS expression without affecting eNOS-mediated NO production.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226385     DOI: 10.1016/s0006-2952(00)00567-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Ganoderma lucidum inhibits inducible nitric oxide synthase expression in macrophages.

Authors:  Connie W H Woo; Ricky Y K Man; Yaw L Siow; Patrick C Choy; Eric W Y Wan; Chak S Lau; Karmin O
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

2.  Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity.

Authors:  Xin-Wei Liu; Jun-Ling Yang; Wei Niu; Wei-Wei Jia; Olajide E Olaleye; Qi Wen; Xiao-Na Duan; Yü-Hong Huang; Feng-Qing Wang; Fei-Fei Du; Chen-Chun Zhong; Yan-Fen Li; Fang Xu; Qi Gao; Li Li; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-07-27       Impact factor: 6.150

3.  Hepatic fibrosis in biliary-obstructed rats is prevented by Ginkgo biloba treatment.

Authors:  Göksel Sener; Levent Kabasakal; Meral Yüksel; Nursal Gedik; Ynci Alican
Journal:  World J Gastroenterol       Date:  2005-09-21       Impact factor: 5.742

4.  Homocysteine stimulates inducible nitric oxide synthase expression in macrophages: antagonizing effect of ginkgolides and bilobalide.

Authors:  Connie W H Woo; Filly Cheung; Vincent W H Chan; Yaw L Siow; Karmin O
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

5.  CB1 as a novel target for Ginkgo biloba's terpene trilactone for controlling chemotherapy-induced peripheral neuropathy (CIPN).

Authors:  Farzaneh Samandar; Zeinab Amiri Tehranizadeh; Mohammad Reza Saberi; Jamshidkhan Chamani
Journal:  J Mol Model       Date:  2022-08-31       Impact factor: 2.172

6.  Endothelium-Independent Vasodilatory Effect of Sailuotong (SLT) on Rat Isolated Tail Artery.

Authors:  S Y Yeon; S W Seto; G H H Chan; M Low; H Kiat; N Wang; J Liu; D Chang
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-22       Impact factor: 2.629

7.  The leaf extract of Ginkgo Biloba L. suppresses oxidized LDL-stimulated fibronectin production through an antioxidant action in rat mesangial cells.

Authors:  Satoshi Akiba; Masahiro Chiba; Yuki Mukaida; Akira Tamura; Takashi Sato
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.